Navigation Links
Reducing Risk and Ensuring Effectiveness in Competitive Intelligence Groups
Date:2/23/2011

CHAPEL HILL, N.C., Feb. 23, 2011 /PRNewswire/ -- Competitive Intelligence (CI) groups play a vital role in helping biopharmaceutical organizations navigate today's volatile business environment. It is CI groups' marketplace insights from primary and secondary research that set an organization's strategic and tactical direction for commercial success. But in the closely regulated pharmaceutical industry, organizations need to have policies and guidelines in place for conducting CI that reduce corporate risk -- but don't inhibit gathering of critical information.

To help companies maintain effective CI groups and safely operate in the current regulatory environment, Best Practices, LLC has published a new report: "Best Practices in Competitive Intelligence: Policies & Guidelines that Reduce Corporate Risks."

This report will help organizations understand:

  • How organizations can optimize their CI operations while working within defined guidelines.
  • How CI organizations work with Legal to develop policies and guidelines.
  • Practices for collection, use and sources of primary data -- including employment of third party vendors for primary data collection.
  • CI resources, staffing and structure.

The study found that marketing, business analytics and medical affairs functions are the leading internal contributors of CI. However, those sources for primary CI are neither as frequently used nor as highly valued as the top external sources, which are medical congresses, vendors and KOLs.

Twenty-seven leaders of Competitive Intelligence and related functions at 22 leading pharmaceutical companies participated in the research project. Field interviews and study analysis produced many observations and benchmarks for organization growth and profitability from effective CI operations. CI leaders can use this research to help create or maintain policies and guidelines regarding CI operations as well as to compare their data collection practices and resource/structural benchmarks with those of leading organizations.

To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1043.htm. For related research, visit our Best Practices, LLC Web site at www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For more than 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information about the company, go to www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutaneous Coronary Interventions
2. DSM Receives European Outsourcing Awards for Carbon Footprint Reducing Technology
3. Daily Intake of Yakult Is Efficacious in Reducing Incidence of Acute Diarrhea in Young Children
4. Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects, New Report Says
5. Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
6. Adult Circumcision Reduces Risk of HIV Transmission Without Reducing Sexual Pleasure
7. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
8. Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use
9. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):